



FINAL

CERVIX CANCER COMMITTEE AGENDA

THURSDAY, OCTOBER 18, 2018, 11:00AM – 12:00PM

CHAIR: BRAD MONK

CO-CHAIR: ANTONIO CASADO

**AMPHITHEATRE, KLINIKUM DER UNIVERSITAT MUENCHEN, DEPARTMENT OF GYNECOLOGY AND OBSTETRICS, CAMPUS
INNENSTATDT, MAISTR. 11, MUNCHEN**

HARMONIZATION LIAISONS: STONEBRAKER/KELLER (OPS), REUSS (STATS)

Please sign Attendance Forms

WELCOME & INTRODUCTIONS

MONK/CASADO

COI DECLARATIONS

APPROVAL OF MINUTES/REPORT: MAY 2018 (POSTED ON GCIG WEBSITE)

MOTION: _____ SECONDED: _____

CLOSED/PUBLISHED TRIALS:

MONK

- Impact of Tumour Histology on survival in advanced cervical carcinoma:
an NRG Oncology/Gynaecologic Oncology Group Study
Br J Cancer. 2018 Jan; 118(2):162-170

ON-GOING CLINICAL TRIALS:

a) ANZGOG

b) BGOG

ENGOT-CX1 RANDOMIZED PHASE II OF PACLITAXEL-CARBOPLATIN +/- NINTEDANIB

VERGOTE

c) CCTG

CONTESSA/NEOCON-F

PLANTE

SHAPE

PLANTE

d) DGOG

GROINSS-VII

CREUTZBERG

GROINSS-VIII

CREUTZBERG

e) GINECO

SENTICOL III

LECURU

f) NRG/GOG-F

NRG 278

MONK

GOG 3009

MONK

NRG GY006

MONK

NRG 279

MONK

GOG 3016

MONK

RTOG 0724

MONK

g) KGOG

GOG 263

RYU

TACO

RYU

h) NCRI

INTERLACE

MCCORMACK

- i) **EORTC**
EORTC 55994
- j) **NSGO**
MARUC

CASADO

MIRZA

UPDATE OF TRIALS IN DEVELOPMENT:

NEW CONCEPTS/PROPOSALS:

- AGOG: A Phase 2 Trial of Pembrolizumab combined with chemoradiation in patients with [¹⁸F]-FDG PET/CT-defined poor-prognostic cervical cancer

Lai

DISCUSSION/FUTURE DIRECTIONS:

MONK/CASADO

ADJOURN